1. O-6-Methylguanine-DNA methyltransferase expression is associated with pituitary adenoma tumor recurrence: a systematic meta-analysis
- Author
-
Yong Yao, Congxin Dai, Xiaohai Liu, Renzhi Wang, Chengxian Yang, Xueyuan Li, Ming Feng, Junji Wei, Xinjie Bao, Wenbin Ma, Bowen Sun, and Kan Deng
- Subjects
Adenoma ,Oncology ,medicine.medical_specialty ,Pathology ,recurrence ,Methyltransferase ,030209 endocrinology & metabolism ,Cochrane Library ,03 medical and health sciences ,0302 clinical medicine ,Pituitary adenoma ,Internal medicine ,aggressive ,Biomarkers, Tumor ,Humans ,Medicine ,Pituitary Neoplasms ,neoplasms ,DNA Modification Methylases ,Temozolomide ,business.industry ,Tumor Suppressor Proteins ,O-6-methylguanine-DNA methyltransferase ,Odds ratio ,Publication bias ,Prognosis ,medicine.disease ,digestive system diseases ,DNA Repair Enzymes ,Case-Control Studies ,030220 oncology & carcinogenesis ,Meta-analysis ,pituitary adenomas ,Neoplasm Recurrence, Local ,MGMT ,business ,Research Paper ,medicine.drug - Abstract
// Congxin Dai 1, * , Bowen Sun 1, * , Xiaohai Liu 1 , Xinjie Bao 1 , Ming Feng 1 , Yong Yao 1 , Junji Wei 1 , Kan Deng 1 , Chengxian Yang 1 , Xueyuan Li 1 , Wenbin Ma 1 , Renzhi Wang 1 1 Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China * These authors have contributed equally to this work Correspondence to: Renzhi Wang, email: Wangrz@126.com Keywords: pituitary adenomas, MGMT, recurrence, aggressive Received: October 07, 2016 Accepted: December 01, 2016 Published: February 01, 2017 ABSTRACT O-6-methylguanine-DNA methyltransferase (MGMT) reportedly counteracts the cytotoxic effects of the alkylating agent temozolomide. MGMT expression is often low in aggressive pituitary adenomas (PAs) and recurrent PAs. However, because these associations are controversial, we performed this meta-analysis to clarify the involvement of MGMT in the prognosis and clinicopathology of PA. We searched for relevant studies in electronic databases (MEDLINE, the Cochrane Library Database, EMBASE, CINAHL, Web of Science and the Chinese Biomedical Database (CBD)) and calculated/pooled the odds ratios (ORs) or standard mean differences (SMDs) with 95% confidence intervals (95% CIs). Eleven case-control studies with a total of 454 PA patients were included. Our meta-analysis revealed that lower expression of MGMT was associated with PA recurrence (OR=2.09, 95% CI=1.09–4.02; p =0.026). On the other hand, MGMT expression was not associated with PA invasiveness (OR=1.112, 95% CI=0.706–1.753; p =0.646), Unexpectedly, MGMT expression could not be used to distinguish functional from non-functional PA patients (OR=1.766, 95% CI=0.938–3.324; p =0.078). The MGMT expression was not found to be related to other clinicopathological indicators of PA including age, gender or tumor size. No publication bias was detected in this meta-analysis (p>0.05). This meta-analysis suggests that MGMT expression may be associated with PA tumor recurrence, but not be related to invasiveness or other clinicopathological indicators. Thus, detection of MGMT expression may facilitate outcome prediction and guide clinical therapy for PA patients.
- Published
- 2017